HN
HNSBF.US Hansa Biopharma AB (publ)
- Market cap
- USD 328M
- P/E
- -
- P/B
- 8.49x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HNSBF.US undervalued?
Graham numberThe Graham number of Hansa Biopharma AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hansa Biopharma AB (publ) fundamental analysis
No fundamental analysis for Hansa Biopharma AB (publ) yet.
Hansa Biopharma AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next gener…
Full company profileHansa Biopharma AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hansa Biopharma AB (publ) annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.58M | 3.44M | 3.36M | 3.36M | 6.10M | 33.9M | 155M | 134M | 171M | 222M | 290M |
| Gross Profit | 2.36M | 3.22M | 2.44M | 2.50M | 5.10M | 18.5M | 116M | 71.0M | 87.8M | 139M | 146M |
| Operating Income | -111M | -176M | -246M | -360M | -423M | -547M | -589M | -788M | -638M | -518M | -605M |
| EBITDA | -108M | -172M | -245M | -352M | -413M | -539M | -554M | -706M | -642M | -371M | -611M |
| Net Income | -111M | -177M | -248M | -360M | -421M | -548M | -611M | -832M | -807M | -534M | -833M |
| EPS | -3.37 | -4.96 | -6.47 | -9.00 | -9.98 | -12 | -14 | -16 | -13 | -6.58 | -8.35 |
| Balance Sheet | |||||||||||
| Total Assets | 311M | 680M | 945M | 664M | 1.43B | 1.01B | 1.69B | 1.02B | 801M | 1.17B | 1.93B |
| Total Liabilities | 27.0M | 49.8M | 84.9M | 101M | 192M | 255M | 1.08B | 1.19B | 1.39B | 1.25B | 2.62B |
| Shareholders' Equity | 284M | 631M | 860M | 563M | 1.24B | 758M | 603M | -168M | -590M | -89.0M | -688M |
| Cash & Short-term Investments | 254M | 616M | 858M | 601M | 1.38B | 889M | 1.50B | 732M | 405M | 701M | 1.34B |
| Total Debt | 48.0K | 403K | 577K | 9.46M | 5.05M | 35.4M | 791M | 867M | 1.08B | 934M | 952M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -94.6M | -150M | -205M | -335M | -290M | -481M | -503M | -756M | -675M | -549M | 873M |
| Capital Expenditure | 984K | 2.41M | 2.49M | 3.43M | 294K | 2.40M | 3.33M | 284K | 116K | 0.00 | 24.9M |
| Free Cash Flow | -95.5M | -153M | -207M | -338M | -291M | -484M | -506M | -756M | -675M | -549M | 848M |
| Ratios | |||||||||||
| ROE | -39.2% | -28.0% | -28.8% | -64.0% | -33.9% | -72.4% | -101.4% | - | - | - | - |
| ROA | -35.8% | -26.0% | -26.2% | -54.2% | -29.3% | -54.1% | -36.2% | -81.7% | -100.8% | -45.8% | -43.1% |
| Net Profit Margin | -4,309.0% | -5,132.5% | -7,384.6% | -10,701.8% | -6,901.5% | -1,618.4% | -395.5% | -620.3% | -470.9% | -240.3% | -286.9% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.02x | 0.00x | 0.05x | 1.31x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hansa Biopharma AB (publ) dividends
Hansa Biopharma AB (publ) has not paid dividends in the last 9 fiscal years.
Who owns Hansa Biopharma AB (publ)
- Insiders 5.72%
- Institutions 48.83%
- Public & others 45.46%
- Shares outstanding 99.7M
- Free float 65.9M
Hansa Biopharma AB (publ) company profile
- Company name
- Hansa Biopharma AB (publ)
- Ticker
- HNSBF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 125
- Fiscal year end
- December
- Address
- Scheelevägen 22, Lund, Sweden, 223 63
- Phone
- 46 46 16 56 70
- Website
- hansabiopharma.com
About Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD) and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was formerly known as Hansa Medical AB (publ) and changed its name to Hansa Biopharma AB (publ) in December 2018. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Hansa Biopharma AB (publ) management
10- Ms. Renee Aguiar-LucanderChief Executive Officer · born 1962
- Mr. Adam D. Cutler B.A.Chief Financial Officer · born 1974
- Ms. Monika TornsenCOO & President of U.S. · born 1978
- Dr. Hitto Kaufmann Ph.D.Chief Scientific & Technology Officer · born 1970
- Ms. Eva-Maria JoedVice President of Finance & Administration · born 1969
- Mr. Klaus SindahlVP & Head of Investor Relations
- Mr. Brian GormanChief Legal Officer & Corporate Secretary · born 1976
- Ms. Sandra FrithiofChief Human Resources Officer · born 1975
- Mr. Emanuel BjörneVP & Head of Business Development · born 1973
- Dr. Lena WinstedtHead of Science · born 1969